EDAP TMS SA (NASDAQ: EDAP) is a medical device company that develops, manufactures, and sells High Intensity Focused Ultrasound (HIFU) systems for the treatment of prostate conditions. Revenue comes primarily from the sale and service of its Focal One HIFU platform, with the company having made a strategic shift as of FY2025 to concentrate on proprietary HIFU activities while reducing emphasis on non-HIFU distribution and extracorporeal shockwave lithotripsy (ESWL) businesses. The Focal One system is classified by the FDA as a Class II device, cleared via the 510(k) pathway, and in 2025 received additional FDA clearance for ultrasound imaging and workflow enhancements to the Focal One i System. EDAP operates internationally, including a Japanese subsidiary that holds a Marketing Authorization Holder license under Japan's Pharmaceuticals and Medical Devices Act. The company has never paid a dividend and carries debt, including borrowings under a Credit Facility that provided net proceeds of $12.4 million in FY2025.

Revenue model

Transactional revenue from sale of Focal One HIFU systems to hospitals and urology centers, supplemented by service and distribution activity. The company is actively winding down third-party distribution and ESWL segments to focus on proprietary HIFU hardware and associated services.

Products and services

Focal One HIFU system (FDA Class II, 510(k)-cleared); Focal One i System with enhanced ultrasound imaging and workflow features (FDA clearance received in 2025); extracorporeal shockwave lithotripsy (ESWL) devices (being de-emphasized as of FY2025); third-party medical device distribution (being wound down).

Customers and end markets

Hospitals, urology centers, and healthcare professionals performing prostate treatments. End market is urological oncology and focal therapy for prostate conditions. Reimbursement inclusion under national health insurance programs, including Japan's MHLW-administered programs, is a demand driver.

Value-chain role

Medical device manufacturer and direct seller. Holds proprietary IP in HIFU technology, manufactures devices, seeks regulatory clearances across multiple jurisdictions, and sells directly to healthcare facilities. Also acts as distributor for third-party devices in select markets, though this role is being reduced.

Geographic exposure

International operations including the United States, Japan (via a wholly-owned subsidiary with Marketing Authorization Holder license), European Union, and other markets. Subject to U.S. FDA regulation, Japanese MHLW regulation, EU medical device regulations, and U.S. export control and sanctions laws.

Source: SEC 10-K, filed 2026-03-25

Industry: Electromedical & Electrotherapeutic Apparatus